Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Carmine Fedele, Shuai Li, Kai Wen Teng, et al.
The Journal of Experimental Medicine (2020) Vol. 218, Iss. 1
Open Access | Times Cited: 200

Showing 26-50 of 200 citing articles:

Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
Zhiyong Xu, Chunyi Guo, Qiaoli Ye, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 76
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura, Md. Hafiz Uddin, Misako Nagasaka, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 819-835
Open Access | Times Cited: 71
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Mı́riam Molina-Arcas, Amit Samani, Julian Downward
Genes (2021) Vol. 12, Iss. 6, pp. 899-899
Open Access | Times Cited: 68
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 63
Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention
Christian W. Johnson, Deborah L. Burkhart, Kevin M. Haigis
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 913-923
Open Access | Times Cited: 62
SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
Anthos Christofides, Xanthi-Lida Katopodi, Carol Cao, et al.
Nature Immunology (2022) Vol. 24, Iss. 1, pp. 55-68
Open Access | Times Cited: 54
Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy
Takamitsu Hattori, Lorenzo Maso, Kiyomi Y. Araki, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 132-145
Open Access | Times Cited: 52
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
Yuanwang Pan, Han Han, Hai Hu, et al.
Cancer Cell (2022) Vol. 41, Iss. 1, pp. 88-105.e8
Open Access | Times Cited: 48
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Joel Encarnación-Rosado, Albert S.W. Sohn, Douglas E. Biancur, et al.
Nature Cancer (2023) Vol. 5, Iss. 1, pp. 85-99
Open Access | Times Cited: 40
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 24
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 9, pp. 1017-1029
Closed Access | Times Cited: 24
Targets of tumor microenvironment for potential drug development
Ling Zhang, Ziruoyu Wang, Kailu Liu, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 11
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 11
Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives
Christos Adamopoulos, Donatella Delle Cave, Athanasios G. Papavassiliou
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1631-1631
Open Access | Times Cited: 10
Building a translational cancer dependency map for The Cancer Genome Atlas
Xu Shi, Christos Gekas, Daniel Verduzco, et al.
Nature Cancer (2024) Vol. 5, Iss. 8, pp. 1176-1194
Open Access | Times Cited: 10
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 10
Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions
Yanguo Shang, Shengnan Fu, Qingjing Hao, et al.
Bioorganic Chemistry (2024) Vol. 144, pp. 107092-107092
Closed Access | Times Cited: 9
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Lee Jy, Richie R. Bhandare, Sai H. S. Boddu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116275-116275
Open Access | Times Cited: 9
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 9
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 10, pp. 1418-1430
Open Access | Times Cited: 8
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Neal S. Akhave, Amadeo B. Biter, David S. Hong
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1345-1352
Open Access | Times Cited: 50
Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Kwan Ho Tang, Shuai Li, Alireza Khodadadi‐Jamayran, et al.
Cancer Discovery (2021) Vol. 12, Iss. 1, pp. 47-61
Open Access | Times Cited: 50
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Junmin Zhang, Jilei Zhang, Qing Liu, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 108050-108050
Closed Access | Times Cited: 45
KRAS: A Druggable Target in Colon Cancer Patients
Francesca Negri, Lorena Bottarelli, Gian Luigi de’Angelis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4120-4120
Open Access | Times Cited: 37
More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C
Caressa Lietman, Melissa L. Johnson, Frank McCormick, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 205-217
Open Access | Times Cited: 32

Scroll to top